Andria ParksHerrera - Renalytix VP Marketing

RNLX Stock  USD 0.41  0.05  13.89%   

Insider

Andria ParksHerrera is VP Marketing of Renalytix AI
Address 1460 Broadway, New York, NY, United States, 10036
Phone646 397 3970
Webhttps://renalytix.com

Renalytix Management Efficiency

The company has return on total asset (ROA) of (0.8568) % which means that it has lost $0.8568 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.7318) %, meaning that it created substantial loss on money invested by shareholders. Renalytix's management efficiency ratios could be used to measure how well Renalytix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1.71 in 2024. Return On Capital Employed is likely to rise to -1.78 in 2024. At this time, Renalytix's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 18 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 7.6 M in 2024.
The company currently holds 12.15 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Renalytix AI has a current ratio of 2.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Renalytix until it has trouble settling it off, either with new capital or with free cash flow. So, Renalytix's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Renalytix AI sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Renalytix to invest in growth at high rates of return. When we think about Renalytix's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gregory MSNational Research Corp
N/A
Barrie BrianAkili Inc
N/A
Helen HrdyNational Research Corp
58
Michael SturmerProgyny
47
Jon BoumsteinNational Research Corp
N/A
Daniel BartonForian Inc
59
Peter AnevskiProgyny
57
Santosh ShanbhagAkili Inc
47
Adam MDAkili Inc
54
Jay SreedharanR1 RCM Inc
N/A
Jona RaaschNational Research Corp
65
David TerrellForian Inc
N/A
Matthew OmernickAkili Inc
N/A
Adam DublinForian Inc
58
Mark GroveForian Inc
N/A
CPA CPANational Research Corp
66
Walter MartucciAkili Inc
42
Julie DiCarloAkili Inc
N/A
Carl GottliebAkili Inc
N/A
Max WygodForian Inc
36
Jonathan DavidAkili Inc
46
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York. Renalytix operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 51 people. Renalytix AI (RNLX) is traded on NASDAQ Exchange in USA. It is located in 1460 Broadway, New York, NY, United States, 10036 and employs 8 people. Renalytix is listed under Health Care Technology category by Fama And French industry classification.

Management Performance

Renalytix AI Leadership Team

Elected by the shareholders, the Renalytix's board of directors comprises two types of representatives: Renalytix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Renalytix. The board's role is to monitor Renalytix's management team and ensure that shareholders' interests are well served. Renalytix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Renalytix's outside directors are responsible for providing unbiased perspectives on the board's policies.
Oliver III, Chief Officer
Jean Casner, VP Officer
Baljit Singh, Head Operations
Howard Doran, Chief Officer
Salim FCA, Company Secretary
Fergus Fleming, Chief Officer
Andria ParksHerrera, VP Marketing
James MBA, Chief Officer

Renalytix Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Renalytix a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Renalytix AI offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Renalytix's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Renalytix Ai Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Renalytix Ai Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Renalytix AI. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Renalytix Stock analysis

When running Renalytix's price analysis, check to measure Renalytix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Renalytix is operating at the current time. Most of Renalytix's value examination focuses on studying past and present price action to predict the probability of Renalytix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Renalytix's price. Additionally, you may evaluate how the addition of Renalytix to your portfolios can decrease your overall portfolio volatility.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Equity Valuation
Check real value of public entities based on technical and fundamental data
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Renalytix's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Renalytix. If investors know Renalytix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Renalytix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.76)
Revenue Per Share
0.046
Quarterly Revenue Growth
(0.26)
Return On Assets
(0.86)
Return On Equity
(10.73)
The market value of Renalytix AI is measured differently than its book value, which is the value of Renalytix that is recorded on the company's balance sheet. Investors also form their own opinion of Renalytix's value that differs from its market value or its book value, called intrinsic value, which is Renalytix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Renalytix's market value can be influenced by many factors that don't directly affect Renalytix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Renalytix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Renalytix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Renalytix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.